Format

Send to

Choose Destination
Pediatr Nephrol. 2018 Feb;33(2):325-333. doi: 10.1007/s00467-017-3787-0. Epub 2017 Sep 12.

Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.

Author information

1
University of Alabama at Birmingham, Birmingham, AL, USA.
2
Jagiellonian University Medical College, Krakow, Poland.
3
Seattle Children's Hospital, Seattle, WA, USA.
4
Oregon Health and Science University, Portland, OR, USA.
5
University of California, Los Angeles, CA, USA.
6
Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
7
University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
8
Sanofi, Cambridge, MA, USA.
9
Editas Medicine, Cambridge, MA, USA.
10
Children's Mercy Kansas City, 2401 Gilham Road, Kansas City, MO, 64108, USA. bwarady@cmh.edu.

Abstract

BACKGROUND:

Treatment for hyperphosphatemia in chronic kidney disease (CKD) involves dietary control of phosphorus intake, dialysis, and treatment with oral phosphate binders, none of which were approved by the Federal Food and Drug Administration in pediatric patients at the time of this study.

METHODS:

This was a phase 2, multicenter study (NCT01574326) with a 2-week, randomized, placebo-controlled, fixed-dose period (FDP) followed by a 6-month, single-arm, open-label, dose-titration period (DTP), with the aim to evaluate the safety and efficacy of sevelamer carbonate (SC) in hyperphosphatemic pediatric patients with CKD. Following a 2-4 week screening phase, pediatric patients with a serum phosphorus level higher than age-appropriate levels were randomized to receive either SC or placebo as powder/tablets in 0.4-1.6 g doses, based on body surface area. The primary efficacy outcome was the change in serum phosphorus from baseline to end of the FDP in the SC versus placebo arms (analysis of covariance). The secondary outcome was mean change in serum phosphorus from baseline to end of DTP by treatment group and overall. Treatment-emergent/serious adverse events (AEs) were recorded.

RESULTS:

Of 101 enrolled patients (29 centers), 66 completed the study. The majority of patients were adolescents (74%; mean age 14.1 years) and on dialysis (77%). Renal transplant was the main reason for discontinuation. SC significantly reduced serum phosphorus from baseline levels (7.16 mg/dL) during the FDP compared to placebo (least square mean difference - 0.90 mg/dL, p = 0.001) and during the DTP (- 1.18 mg/dL, p < 0.0001). The safety and tolerability of SC and placebo were similar during the FDP, with patients in both groups reporting mild/moderate gastrointestinal AEs during the DTP.

CONCLUSIONS:

Sevelamer carbonate significantly lowered serum phosphorus levels in hyperphosphatemic children with CKD, with no serious safety concerns identified.

KEYWORDS:

Chronic kidney disease; Hyperphosphatemia; Pediatric patients; Phosphate binder; Sevelamer carbonate

PMID:
28900759
DOI:
10.1007/s00467-017-3787-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center